Chronic kidney disease (CKD) affects millions, especially in low- and middle-income countries, where many die early due to lack of treatment. One group of medicines, called SGLT2 inhibitors (SGLT2i), have been shown to slow down kidney damage and reduce the risk of heart-related deaths. The IMPLEMENT-CKD project will work with communities in Thailand, Fiji and Samoa to make it easier for people with CKD or type 2 diabetes to get these life-saving medicines as part of their regular care.
chronic kidney disease (CKD) with eGFR > 20 mL/min/1.73m²;
type 2 diabetes mellitus (T2DM).
Nil
Participants will be recruited from Thailand, Fiji and Samoa.
Other
Prospective
Implementation of recommendations
Other interventionThe study will be organised into three periods: * A pre-implementation phase - co-design implementation strategies development in each region; * An implementation phase - initiation of SGT2i and evaluation; * A post-implementation phase - consolidate learnings and dissemination for scaling up
A Reach of 50% of eligible patients initiated on SGLT2i therapy
Proportion of eligible patients initiated on SGLT2i therapy, calculated as number of patients who were prescribed SGLT2i therapy during the intervention period/ number of patients meeting predefined eligibility criteria.
Adherence to SGLT2i therapy
Patient reported uptake
Effectiveness
Rates of CKD detection
Adoption
% of participating centres that initiate implementation strategies.
Implementation
Acceptability and feasibility of implementation strategies. Fidelity to protocol
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
